Last updated: February 26, 2026
What is the Drug with NDC 00004-0259?
ND a National Drug Code (NDC) identifier, which uniquely identifies a specific pharmaceutical product. NDC 00004-0259 refers to Humira (Adalimumab), a monoclonal antibody used to treat autoimmune diseases including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and ankylosing spondylitis.
Market Landscape of Adalimumab
Market Size and Revenue
Humira was the best-selling drug globally before its patent expiration in 2023. In 2022, its estimated global sales reached $21 billion, split across North America (roughly 60%), Europe (about 25%), and other markets[1].
Competitive Environment
Humira faces competition from biosimilars and other biologics. Biosimilar entry began in early 2023, notably:
- Amgen’s Amjevita (adalimumab-atto)
- Boehringer Ingelheim’s Cyltezo
These biosimilars have gained market share but still represent a fraction of Humira’s revenue, estimated at around 15-20% of U.S. prescriptions as of the latest data[2].
Regulatory and Patent Landscape
Humira’s patents expired or are invalidated in multiple jurisdictions, enabling biosimilar competition. The U.S. market saw biosimilar approvals starting in late 2022, with initial launches in early 2023. Patent litigations continue in some regions but have had minimal long-term impact on market penetration.
Price Dynamics
Originator Price Trends
In the U.S., Humira’s list price was approximately $6,000 per month in 2022, before rebates and discounts. Actual patient out-of-pocket costs were lower due to insurance coverage, with net prices significantly reduced.
Biosimilar Price Adjustments
Biosimilars launched at 10-20% lower than Humira’s price in many markets, with some entering the U.S. at starting prices of approximately $5,000 per month[3]. The presence of biosimilars has put downward pressure on prices, but the extent varies by region and formulary.
Price Projections
-
2023-2024: Biosimilar competition will likely result in a 20-30% reduction in U.S. list prices for adalimumab products.
-
Post-2024: As biosimilar market share grows, further price erosion could approach 40-50% compared to pre-2023 levels, assuming manufacturing costs remain stable.
-
Market Share Shift: Biosimilars are expected to capture 50-60% of the adalimumab market in the U.S. within the next 2 years, accelerating price declines[4].
Forecasting the Market
| Year |
Estimated Humira Revenue |
Biosimilar Market Share |
Average Price per Unit |
Key Drivers |
| 2023 |
$12-14 billion |
20% |
$5,000-$6,000/month |
Biosimilar entry, patent expiry |
| 2024 |
$8-10 billion |
50-60% |
$4,000-$5,000/month |
Increased biosimilar adoption |
| 2025+ |
Decline continues |
70%+ |
$3,500/month and lower |
Market penetration, discounts |
Pricing Variations by Region
- United States: Higher list prices, significant discounts via rebates. Biosimilar uptake is rapid but moderated by insurer negotiations.
- Europe: Prices are regulated; biosimilar market penetration faster, with discounts of 25-35% compared to originator.
- Emerging Markets: Lower prices due to regulatory controls and affordability programs.
Risks and Opportunities
- Biosimilar Uptake: Slower than expected could stabilize prices.
- Regulatory Changes: Patent extensions or legal litigations could delay biosimilar impact.
- Therapeutic Advancements: New treatments may reduce demand for Humira.
Key Takeaways
- Humira’s market revenue peaked pre-2023, with a rapid decline expected due to biosimilar competition.
- List prices for adalimumab are projected to decrease by 20-50% over the next two years.
- Biosimilar market share in the U.S. should reach 50-60% within 2 years, exerting significant pricing pressure.
- Regional regulations heavily influence pricing and market penetration strategies.
- Future revenue depends on the pace of biosimilar adoption and potential label expansions.
FAQs
1. How will biosimilar competition impact Humira’s price?
Biosimilars are expected to lower prices by 20-50% in the U.S. over the next 2 years, with increased market share and discounts.
2. What are the main regions driving price decline?
The U.S. and Europe will see the most significant reductions, driven by biosimilar entry and regulatory policies.
3. Are biosimilars expected to fully replace Humira?
Biosimilars are expected to capture majority market share, but some branded patient or physician preferences may sustain higher prices for the originator.
4. Does patent expiry guarantee price decline?
Patent expiry enables biosimilar entry; however, legal challenges and market dynamics will influence the pace and extent of price reductions.
5. What are the potential upside opportunities for new entrants?
Emerging biosimilars with patented innovations or superior delivery methods could capture additional market share and command premium pricing.
References
[1] IQVIA. (2022). Global Medicine Sales Data.
[2] EvaluatePharma. (2023). Biologic and Biosimilar Market Dynamics.
[3] Xinhua. (2023). Biosimilar Pricing Strategies.
[4] FMV Research. (2023). Biosimilar Adoption Rates in U.S.
